Уважаемый Владимир Яковлевич,
Удосужились ли Вы поинтересоваться перед Вашим эффектным и долгим выступлением, что случилось с ЕДТА терапией после 1989? Задались ли Вы вопросом, почему книга руководителя Секции Пищи так и осталась невостребованной? Думаю, что нет, т.к. в очередной рад Вы выкопали себе яму. Зачем это Вам? Я право не знаю... Прочитайте эти статьи.
1. Am Coll Cardiol. 2003 Feb 5;41(3):420-5.
Effect of chelation therapy on endothelial function in patients with coronary artery disease: PATCH substudy.
Anderson TJ, Hubacek J, Wyse DG, Knudtson ML.
Faculty of Medicine, University of Calgary and Calgary Health Region, 1403 29th Street NW, Calgary, Alberta T2N 2T9, Canada. [Ссылки доступны только зарегистрированным пользователям ]
OBJECTIVES: The purpose of this study was to evaluate the effect of chelation therapy with ethylenediamine tetraacetic acid (EDTA) on endothelium-dependent vasomotor responses in patients with documented coronary artery disease (CAD). BACKGROUND: Oxidative stress plays an important role in the dysfunction of endothelium and development of atherosclerosis. Modification of cardiac risk factors and employment of antioxidants have been shown to improve endothelial function. Ethylenediamine tetraacetic acid chelation therapy is considered to be a complementary therapy for patients with CAD and is proposed to have antioxidant properties. METHODS: A total of 47 patients enrolled in the Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) participated in this substudy and had complete data. High-resolution ultrasound was used to assess endothelium-dependent brachial artery flow-mediated vasodilation (FMD) in patients with CAD in a randomized, double-blind, and placebo-controlled fashion. Patients were randomized to chelation therapy or placebo. The primary end point was the absolute difference in FMD after the first and 33rd treatments (6 months) of study groups compared with their baselines. RESULTS: At the baseline, the study population had mild impairment of FMD (7.2 +/- 3.4%). The first chelation treatment did not change FMD as compared with placebo (chelation 6.5 +/- 3.5% vs. placebo 7.4 +/- 2.9%; p value = 0.371). The brachial artery studies at six months did not demonstrate significant differences in FMD between study groups (placebo 7.3 +/- 3.4% vs. chelation 7.3 +/- 3.2%; p value = 0.961).
CONCLUSIONS: Our results suggest that EDTA chelation therapy in combination with vitamins and minerals does not provide additional benefits on abnormal vasomotor responses in patients with CAD optimally treated with proven therapies for atherosclerotic risk factors.
2. Heart Advis. 2003 Apr;6(4):2.
Another test, another disappointment for chelation therapy.
3. JAMA. 2002 Jan 23-30;287(4):481-6.
Chelation therapy for ischemic heart disease: a randomized controlled trial.
Knudtson ML, Wyse DG, Galbraith PD, Brant R, Hildebrand K, Paterson D, Richardson D, Burkart C, Burgess E; Program to Assess Alternative Treatment Strategies to Achieve Cardiac Health (PATCH) Investigators.
Foothills Medical Center, 1403 29th St NW, Calgary, Alberta, Canada T2N 2T9. [Ссылки доступны только зарегистрированным пользователям ]
CONTEXT: Chelation therapy using EDTA is an unproven but widely used alternative therapy for ischemic heart disease. OBJECTIVE: To determine if current EDTA protocols have a favorable impact on exercise ischemia threshold and quality of life measures in patients with stable ischemic heart disease. DESIGN: Double-blind, randomized, placebo-controlled trial conducted between January 1996 and January 2000. SETTING: Participants were recruited from a cohort of cardiac catheterization patients and the practices of cardiologists in Calgary, Alberta. PARTICIPANTS: We screened 3140 patients, performed a qualifying treadmill test in 171, and enrolled 84. Entry criteria included age at least 21 years with coronary artery disease proven by angiography or a documented myocardial infarction and stable angina while receiving optimal medical therapy. The required treadmill test used a gradual ramping protocol and patients had to demonstrate at least 1-mm ST depression. INTERVENTIONS: Patients were randomly assigned to receive infusion with either weight-adjusted (40 mg/kg) EDTA chelation therapy (n = 41) or placebo (n = 43) for 3 hours per treatment, twice weekly for 15 weeks and once per month for an additional 3 months. Patients in both groups took oral multivitamin therapy as well. MAIN OUTCOME MEASURE: Change from baseline to 27-week follow-up in time to ischemia (1-mm ST depression). RESULTS: Thirty-nine patients in each group completed the 27-week protocol. One chelation patient had therapy discontinued for a transient rise in serum creatinine. The mean (SD) baseline exercise time to ischemia was 572 (172) and 589 (176) seconds in the placebo and chelation groups, respectively. The corresponding mean changes in time to ischemia at 27 weeks were 54 seconds (95% confidence interval [CI], 23-84 seconds; P<.001) and 63 seconds (95% CI, 29-95 seconds; P<.001), for a difference of 9 seconds (95% CI, -36 to 53 seconds; P =.69). Exercise capacity and quality of life scores improved by similar degrees in both groups. CONCLUSION: Based on exercise time to ischemia, exercise capacity, and quality of life measurements, there is no evidence to support a beneficial effect of chelation therapy in patients with ischemic heart disease, stable angina, and a positive treadmill test for ischemia.
4. Am Heart J. 2000 Jul;140(1):139-41
Chelation therapy for coronary heart disease: An overview of all clinical investigations.
Ernst E.
Department of Complementary Medicine, School of Postgraduate Medicine and Health Sciences, University of Exeter, United Kingdom. [Ссылки доступны только зарегистрированным пользователям ]
BACKGROUND: Chelation therapy is popular in the United States. The question of whether it does more good than harm remains controversial. AIM: The aim of this systematic review was to summarize all the clinical evidence for or against the effectiveness and efficacy of chelation therapy for coronary heart disease. METHODS: A thorough search strategy was implemented to retrieve all clinical investigations regardless of whether they were controlled or uncontrolled. RESULTS: The most striking finding is the almost total lack of convincing evidence for efficacy. Numerous case reports and case series were found. The majority of these publications seem to indicate that chelation therapy is effective. Only 2 controlled clinical trials were located. They provide no evidence that chelation therapy is efficacious beyond a powerful placebo effect. CONCLUSION: Given the potential of chelation therapy to cause severe adverse effects, this treatment should now be considered obsolete.
"Chelation therapy cannot be recommended as a useful treatment for coronary heart desease (CHD). Numerous uncontroled investigations report symptomatic improvement, whereas the only 2 controled suggest that these benefits are caused by placebo effect. In view of its potential risks, chelation therapy for CHD should be discarded in favor of therapies of proven efficacy".
На этом разрешите оставить Вас в компании хамоватого гостя (65.172.164.2) и хламидийного короля.
Прощайте,
Е.Е.Студенцов